AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors

Group 1 - AstraZeneca's share price has increased by 6% over the past four months since the last article was published [1] Group 2 - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in various sectors including ETFs, commodities, technology, and pharmaceuticals [2] - The firm aims to simplify investment strategies for both seasoned and novice investors, fostering a community of informed investors [2]